2 February 2025 - The Australian Government is listing Retevmo (selpercatinib) on the PBS for the first time to treat advanced or metastatic rearranged during transfection fusion positive non-small cell lung cancer.

Around 130 Australian patients are expected to benefit from this listing each year. Without the PBS subsidy, they could pay more than $280,000 for a course of treatment.

Read Minister for Health press release